Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.33 |
| ▸ | MME | P08473 | 3/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.32 |
| ▸ | ITGAV | P06756 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438372 | 0.86 | NPC1 (0.37) | NPC1RAB9AITGB1ITGA5MME | |
| SCHEMBL438371 | 0.86 | NPC1 (0.37) | NPC1RAB9AITGB1ITGA5MME | |
| SCHEMBL5784715 | 0.80 | NPC1 (0.37) | NPC1RAB9AITGB1ITGA5MME | |
| SCHEMBL7105865 | 0.76 | MEN1 (0.42) | NPC1RAB9ACA2 | |
| SCHEMBL438370 | 0.73 | NPC1 (0.35) | NPC1RAB9AITGB1ITGA5MME | |
| SCHEMBL438991 | 0.72 | MEN1 (0.43) | NPC1RAB9ACA2 | |
| SCHEMBL438992 | 0.72 | MEN1 (0.43) | NPC1RAB9ACA2 | |
| SCHEMBL437797 | 0.71 | KMT2A (0.38) | NPC1RAB9AITGB1CA2 | |
| SCHEMBL443089 | 0.71 | KMT2A (0.38) | NPC1RAB9AITGB1CA2 | |
| SCHEMBL437798 | 0.71 | KMT2A (0.38) | NPC1RAB9AITGB1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8491906-B2 | Selective targeting of tumor vasculature using antibody molecules | PHILOGEN S.P.A. (IT) | 2013-07-23 | — | — | US | disclosed |
| EP-1663320-B1 | TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY L19 AGAINST FIBRONECTIN ED-B | PHILOGEN SPA (IT) | 2011-03-02 | — | — | EP | disclosed |
| EP-2246070-A2 | Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b | Philogen S.p.A. (IT) | 2010-11-03 | — | — | EP | disclosed |
| EP-2239274-A1 | New methods for diagnosis and treatment of tumours | Bayer Schering Pharma AG (DE) | 2010-10-13 | — | — | EP | disclosed |
| EP-1461360-B1 | CONJUGATES COMPRISING AN ANTIBODY SPECIFIC FOR THE ED-B DOMAIN OF FIBRONECTIN AND THEIR USE FOR THE DETECTION AND TREATMENT OF TUMOURS | BAYER SCHERING PHARMA AG (DE) | 2010-08-18 | — | — | EP | disclosed |
| EP-2174958-A1 | Antibodies derived from anti ed-b l19 and targeting tumor vasculature | Philogen S.p.A. (IT) | 2010-04-14 | — | — | EP | disclosed |
| EP-1483297-B1 | ANTIBODIES DERIVED FROM ANTI ED-B L19 AND TARGETING TUMOR VASCULATURE | PHILOGEN SPA (IT) | 2009-12-23 | — | — | EP | disclosed |
| US-20090214423-A1 | SELECTIVE TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY MOLECULES | BORSI LAURA | 2009-08-27 | — | — | US | disclosed |
| US-20060057146-A1 | Selective targeting of tumor vasculature using antibody molecules | PHILOGEN (IT) | 2006-03-16 | — | — | US | disclosed |
| US-20050074401-A1 | Selective targeting of tumor vasculature using radiolabelled antibody molecules | SCHERING AG (DE) | 2005-04-07 | — | — | US | disclosed |
| EP-1514561-A1 | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B | Philogen S.p.A. (IT) | 2005-03-16 | — | — | EP | disclosed |
| US-20040001790-A1 | Methods for diagnosis and treatment of tumours | SCHERING AG (DE) | 2004-01-01 | — | — | US | disclosed |